{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:56:40Z","timestamp":1777586200653,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"3-4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Eur J Mass Spectrom (Chichester)"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    A high-performance liquid chromatography-tandem mass spectrometry method has been developed for the quantification of ertugliflozin in human plasma, employing ertugliflozin D5 as the internal standard. Methyl tertiary butyl ether-based liquid-liquid extraction technique was employed, followed by chromatographic separation on Kromasil-C\n                    <jats:sub>18<\/jats:sub>\n                    (100\u2009\u00d7\u20094.6 mm, 5 \u00b5m) column using a mixture of methanol and 10 mM ammonium formate buffer (80:20, v\/v) as the mobile phase at a flow rate of 1 mL\/min. The mass transitions were observed from\n                    <jats:italic>m<\/jats:italic>\n                    \/\n                    <jats:italic>z<\/jats:italic>\n                    437.4 to 329.2 for ertugliflozin and from\n                    <jats:italic>m<\/jats:italic>\n                    \/\n                    <jats:italic>z<\/jats:italic>\n                    442.2 to 334.3 for ertugliflozin D5 by multiple reaction monitoring in a positive ion electro spray ionization source. The linearity was established in the concentration range of 1\u2013500 ng\/mL, with the correlation coefficient,\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009\n                    <jats:bold>&gt;<\/jats:bold>\n                    \u20090.99. Validation of the method was performed as per US FDA guidelines, and the results were found well within the acceptance limits. The method was applied successfully for the pharmacokinetic study of ertugliflozin 15\u2005mg after a single oral dose under fasting conditions in healthy male volunteers. The\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    and\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    values obtained were 288.28\u2005ng\/mL and 1.32\u2005h, respectively. Authentication of the results was further done by the incurred sample reanalysis.\n                  <\/jats:p>","DOI":"10.1177\/14690667251359789","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:07:17Z","timestamp":1752570437000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid chromatography-tandem mass spectrometry method for quantification of ertugliflozin in human plasma: Application to disposition kinetics"],"prefix":"10.1177","volume":"31","author":[{"given":"Viritha","family":"Bezawada","sequence":"first","affiliation":[{"name":"Department of Engineering Chemistry, College of Engineering, Andhra University, Visakhapatnam, AP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padma","family":"Mogili","sequence":"additional","affiliation":[{"name":"Department of Engineering Chemistry, College of Engineering, Andhra University, Visakhapatnam, AP, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-9085","authenticated-orcid":false,"given":"Sireesha","family":"Dodda","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis, School of Pharmacy, Anurag University, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasa Rao","family":"Polagani","sequence":"additional","affiliation":[{"name":"Analys Lab Private Limited, Hyderabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13251"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2019.05.023"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049551"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.014"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12549"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000171"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040675"},{"key":"e_1_3_2_9_2","first-page":"2021","article-title":"Development and validation of a method for simultaneous estimation of sitagliptin and ertugliflozin in rat plasma by LC-MS method","volume":"17","author":"Venkateswara RP","year":"2021","unstructured":"Venkateswara RP, Lakshmana RA, Prasad SVUM. Development and validation of a method for simultaneous estimation of sitagliptin and ertugliflozin in rat plasma by LC-MS method. Curr Pharm Anal 2021; 17: 2021.","journal-title":"Curr Pharm Anal"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4103\/epj.epj_14_20"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2018.12.016"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.955"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac302919t"},{"key":"e_1_3_2_14_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). May 2018 Bioanalytical Method Validation Guidance for Industry Available at: https:\/\/www.fda.gov\/media\/70858."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2023.109815"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2025.124576"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.06.004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3690"},{"key":"e_1_3_2_19_2","article-title":"Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS\/MS method and its application to a bioequivalence study","volume":"32","author":"Mamdouh RR","year":"2018","unstructured":"Mamdouh RR, Kamal AB. Quantification of amlodipine and atorvastatin in human plasma by UPLC-MS\/MS method and its application to a bioequivalence study. Biomed Chromatogr 2018; 32: e4224.","journal-title":"Biomed Chromatogr"},{"key":"e_1_3_2_20_2","article-title":"Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS\/MS method: application to a bioequivalence study","volume":"32","author":"Mamdouh RR","year":"2018","unstructured":"Mamdouh RR, Emad BB, Kamal AB. Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC-MS\/MS method: application to a bioequivalence study. Biomed Chromatogr 2018; 32: e4347.","journal-title":"Biomed Chromatogr"},{"key":"e_1_3_2_21_2","article-title":"Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS\/MS method: application to a bioequivalence study","volume":"35","author":"Mamdouh RR","year":"2021","unstructured":"Mamdouh RR, Kamal AB. Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC-MS\/MS method: application to a bioequivalence study. Biomed Chromatogr 2021; 35: e5048.","journal-title":"Biomed Chromatogr"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123363"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115165"}],"container-title":["European Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667251359789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14690667251359789","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667251359789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:04:43Z","timestamp":1777406683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/14690667251359789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/14690667251359789"],"URL":"https:\/\/doi.org\/10.1177\/14690667251359789","relation":{},"ISSN":["1469-0667","1751-6838"],"issn-type":[{"value":"1469-0667","type":"print"},{"value":"1751-6838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}